bioAffinity Technologies Inc.
BIAF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BIAF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BIAF
bioAffinity Technologies Inc. (BIAF) is a diagnostics and therapeutics company focused on developing and commercializing non-invasive tests for early-stage cancer, with its lead product CyPath® Lung now generating revenue through a U.S. beta launch.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for bioAffinity Technologies Inc..
bioAffinity Technologies Inc. (BIAF) is a diagnostics and therapeutics company focused on developing and commercializing non-invasive tests for early-stage cancer, with its lead product CyPath® Lung now generating revenue through a U.S. beta launch.
- Lead product CyPath® Lung is a diagnostic test for lung cancer; more than 600 tests were delivered in 2024, and unit sales and revenues more than doubled in 2025 [sec · filed 2026-06-12].
- Cash & equivalents were $2.4M as of 2026-06-30; total revenue for the six months ended June 30, 2026 was $1.5M, with a net loss of $3.4M [sec].
- The company has an accumulated deficit and has stated it needs to raise additional capital to continue operations; its ability to continue as a going concern is dependent on generating revenue and raising financing [sec_mda · as of 2026-08-07].
- bioAffinity is also researching novel cancer therapeutic approaches targeting squamous and basal cell skin cancers, with plans to seek strategic partners for in vivo studies [sec_mda · as of 2026-08-07].
- The business plan includes phased expansion in the U.S., EU, and Asia, with a beta launch in Texas and a planned expansion into the Mid-Atlantic market in 2025 [sec · filed 2026-06-12].
What works
- CyPath® Lung has shown quarter-over-quarter sales growth in its pilot marketing program, with more than 600 tests delivered in 2024 and revenues tripling in 2025 [sec · filed 2026-06-12].
- The company has a clear phased expansion strategy for the U.S., EU, and Asia, designed to maximize resources and minimize market risk [sec · filed 2026-06-12].
- bioAffinity is advancing a therapeutic pipeline targeting skin cancers, with research being conducted at its wholly owned subsidiary PPLS [sec_mda · as of 2026-08-07].
What to weigh
- The company has a history of net losses and an accumulated deficit; as of 2026-06-30, it reported a net loss of $3.4M for the six-month period [sec].
- Cash & equivalents of $2.4M as of 2026-06-30 are limited, and management states that additional financing is required to continue operations and implement the business plan [sec_mda · as of 2026-08-07].
- There is substantial doubt about the company's ability to continue as a going concern if it cannot raise sufficient capital or significantly increase revenue [sec_mda · as of 2026-08-07].
- The company is in the preliminary phases of developing therapeutic products and may never succeed in generating significant income from them [sec · filed 2026-06-12].
From the filings
Quoted directly from source documents.
CyPath® Lung pilot program showed sales growth and more than 600 tests delivered in 2024.
“In January 2025, we reported successful results from the Company's CyPath ® Lung pilot marketing program using Texas for our beta launch with sales growth quarter-over-quarter and more than 600 tests delivered in 2024.”
SEC filings · June 12, 2026
The company needs to raise additional capital to continue operations.
“We believe that we must raise additional funds to be able to continue our business operations.”
SEC filings · June 12, 2026
The company's ability to continue as a going concern is uncertain.
“Our ability to continue as a going concern is dependent upon our ability to generate revenue and raise capital from financing transactions.”
SEC filings · August 7, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company may not be able to continue as a going concern if it cannot raise capital or increase revenue sufficiently [sec_mda · as of 2026-08-07].
- Limited cash runway — Cash & equivalents of $2.4M as of 2026-06-30 may not be sufficient to fund operations without additional financing [sec].
- Dependence on CyPath® Lung — The company's near-term revenue is heavily reliant on the commercial success of a single diagnostic test, CyPath® Lung [sec · filed 2026-06-12].
- Therapeutic pipeline early stage — Therapeutic candidates are in preliminary phases and may never reach clinical trials or generate revenue [sec · filed 2026-06-12].
What to watch
- Progress of CyPath® Lung sales expansion into the Mid-Atlantic market in 2025 [sec · filed 2026-06-12].
- Ability to raise additional capital through equity, debt, or strategic partnerships [sec_mda · as of 2026-08-07].
- Advancement of therapeutic research for skin cancers into in vivo studies and potential partnership announcements [sec_mda · as of 2026-08-07].
- Quarterly revenue and cash burn trends, especially as the company scales commercialization [sec_mda · as of 2026-08-07].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run bioAffinity Technologies Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available bioAffinity Technologies Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.7 months
D/E 1.02 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$927K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 111,086 | $425K |
| geode capital management, llc | 48,293 | $185K |
| vanguard fiduciary trust co | 31,071 | $119K |
| schonfeld strategic advisors llc | 24,413 | $94K |
| state street corp | 14,386 | $55K |
| northern trust corp | 12,725 | $49K |
| citigroup inc | 57 | $218 |
| morgan stanley | 3 | $11 |
| caitong international asset management co., ltd | 1 | $4 |
Short Interest
as of May 20, 2026- % of float
- 11.7%
- Days to cover
- 0.0
- Shares short
- 515,756
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BIAF short interestGovernance
Frequently asked questions
What is the AI investment thesis for bioAffinity Technologies Inc.?
bioAffinity Technologies Inc. (BIAF) is a diagnostics and therapeutics company focused on developing and commercializing non-invasive tests for early-stage cancer, with its lead product CyPath® Lung now generating revenue through a U.S. beta launch.
Who is the CEO of bioAffinity Technologies Inc.?
Ms. Maria Zannes J.D. is the chief executive officer of bioAffinity Technologies Inc. (BIAF).
Where is bioAffinity Technologies Inc. headquartered?
bioAffinity Technologies Inc. (BIAF) is headquartered in San Antonio, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.